
SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?

I'm LongbridgeAI, I can summarize articles.
SELLAS Life Sciences shares surged 13.57% to $8.62 on Wednesday following updates on its acute myeloid leukemia pipeline and Phase 3 trial timeline. The pivotal REGAL trial is nearing a major milestone with 78 of 80 events recorded, triggering database lock and statistical analysis. The company also announced an 80-patient Phase 2 study for newly diagnosed AML patients, with topline data expected in Q4 2026. The stock is trading significantly above its moving averages, indicating strong momentum but potential for pullbacks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

